X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9949) 9949
Magazine Article (36) 36
Book Chapter (13) 13
Publication (7) 7
Conference Proceeding (2) 2
Dissertation (2) 2
Newsletter (2) 2
Newspaper Article (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (6928) 6928
benzimidazoles - therapeutic use (6647) 6647
male (4375) 4375
female (3897) 3897
animals (3594) 3594
middle aged (2404) 2404
benzimidazoles - pharmacology (2268) 2268
adult (1913) 1913
aged (1897) 1897
benzimidazoles - administration & dosage (1708) 1708
pharmacology & pharmacy (1562) 1562
benzimidazoles - adverse effects (1442) 1442
treatment outcome (1440) 1440
dabigatran (1177) 1177
hypertension - drug therapy (1058) 1058
anthelmintics - therapeutic use (972) 972
tetrazoles - therapeutic use (959) 959
rats (946) 946
mice (909) 909
angiotensin ii type 1 receptor blockers - therapeutic use (870) 870
drug therapy, combination (866) 866
benzoates - therapeutic use (843) 843
beta-alanine - analogs & derivatives (834) 834
antihypertensive agents - therapeutic use (833) 833
double-blind method (753) 753
hypertension (709) 709
dose-response relationship, drug (696) 696
blood pressure - drug effects (694) 694
anticoagulants - therapeutic use (686) 686
peripheral vascular disease (685) 685
administration, oral (676) 676
analysis (611) 611
2-pyridinylmethylsulfinylbenzimidazoles (608) 608
adolescent (579) 579
drug therapy (573) 573
beta-alanine - therapeutic use (564) 564
cardiac & cardiovascular systems (564) 564
benzimidazoles - pharmacokinetics (563) 563
oncology (563) 563
time factors (548) 548
telmisartan (536) 536
aged, 80 and over (535) 535
angiotensin-converting enzyme inhibitors - therapeutic use (524) 524
benzimidazoles (520) 520
omeprazole - analogs & derivatives (513) 513
gastroenterology & hepatology (497) 497
medicine, general & internal (493) 493
efficacy (492) 492
rivaroxaban (487) 487
benzimidazole (476) 476
sheep (476) 476
clinical trials as topic (472) 472
risk factors (465) 465
stroke - prevention & control (457) 457
warfarin (449) 449
cancer (447) 447
research (447) 447
care and treatment (434) 434
prevention (430) 430
drug resistance (429) 429
veterinary sciences (427) 427
atrial fibrillation - drug therapy (426) 426
benzimidazoles - chemistry (424) 424
mebendazole - therapeutic use (422) 422
therapy (419) 419
abridged index medicus (414) 414
morpholines - therapeutic use (414) 414
health aspects (410) 410
parasitology (404) 404
medicine & public health (402) 402
pyridines - therapeutic use (398) 398
thiophenes - therapeutic use (392) 392
candesartan (391) 391
anti-ulcer agents - therapeutic use (387) 387
antiviral agents - therapeutic use (382) 382
prospective studies (380) 380
randomized controlled trials as topic (374) 374
double-blind (369) 369
feces - parasitology (368) 368
pharmacokinetics (365) 365
albendazole (361) 361
child (360) 360
cell line, tumor (356) 356
hypertension - physiopathology (353) 353
anticoagulants (348) 348
proton pump inhibitors (347) 347
omeprazole (341) 341
atrial fibrillation (340) 340
disease models, animal (337) 337
cattle (335) 335
warfarin - therapeutic use (335) 335
stroke (333) 333
chemistry, medicinal (329) 329
tetrazoles - pharmacology (328) 328
angiotensin ii type 1 receptor blockers - pharmacology (327) 327
atrial fibrillation - complications (327) 327
anticoagulants - adverse effects (323) 323
angiotensin receptor antagonists (322) 322
angiotensin (321) 321
benzoates - pharmacology (321) 321
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8896) 8896
German (306) 306
Russian (283) 283
French (161) 161
Japanese (125) 125
Spanish (112) 112
Chinese (53) 53
Italian (36) 36
Polish (34) 34
Portuguese (23) 23
Czech (22) 22
Dutch (17) 17
Hungarian (14) 14
Swedish (10) 10
Danish (9) 9
Slovak (8) 8
Ukrainian (8) 8
Turkish (7) 7
Finnish (6) 6
Korean (4) 4
Romanian (4) 4
Afrikaans (2) 2
Bulgarian (2) 2
Arabic (1) 1
Croatian (1) 1
Hebrew (1) 1
Lithuanian (1) 1
Norwegian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European urology, ISSN 0302-2838, 2017, Volume 71, Issue 3, pp. 426 - 436
...), the most effective therapeutic approach for patients with non-clear cell RCC (non-ccRCC) is unknown. Objective To systematically review relevant literature comparing... 
Urology | Papillary | Systematic review | Sunitinib | Non-clear cell renal cell carcinoma | Everolimus | Chromophobe | carcinoma | Review | Non-clear cell renal cell | Journal Article | UROLOGY & NEPHROLOGY | PHASE-II | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Bevacizumab - therapeutic use | Humans | Interleukin-2 - therapeutic use | Antineoplastic Agents - therapeutic use | Interferons - therapeutic use | Comparative Effectiveness Research | Quinolones - therapeutic use | Everolimus - therapeutic use | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Benzimidazoles - therapeutic use | Pyridines - therapeutic use | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Carcinoma, Renal Cell - pathology | Pyrrolidinones - therapeutic use | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Disease-Free Survival | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Indoles - therapeutic use | Kidney Neoplasms - pathology | Erlotinib Hydrochloride - therapeutic use | Quinolines - therapeutic use | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Medical colleges | Care and treatment | Carcinoma, Renal cell | Endothelial growth factors | Analysis | Endothelium | Urologi och njurmedicin | Medical and Health Sciences | Medicin och hälsovetenskap | Klinisk medicin | Clinical Medicine | Cancer and Oncology | Urology and Nephrology | Cancer och onkologi
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2015, Volume 10, Issue 7, p. e0133236
Serum levels of the interferon (IFN)-stimulated chemokine CXCL10 are increased during chronic HCV infection and associate with outcome of IFN-based therapy.... 
VIRUS-INFECTION | CHEMOKINES | MULTIDISCIPLINARY SCIENCES | CHRONIC HEPATITIS-C | PROTEIN-10 | GENOTYPE 1 INFECTION | PREDICTIVE-VALUE | RIBAVIRIN | INDUCTION | ASSOCIATION | SPONTANEOUS CLEARANCE | Recurrence | Interferons | Humans | Fluorenes - therapeutic use | Dipeptidyl Peptidase 4 - blood | Hepatitis C, Chronic - virology | Male | Adult | Female | Hepacivirus - physiology | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Virus Replication - drug effects | Chemokine CXCL10 - blood | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Dipeptidyl Peptidase 4 - genetics | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - blood | Convalescence | Chemokine CXCL10 - genetics | Protein Processing, Post-Translational | Hepatitis C, Chronic - genetics | Viral Load - drug effects | Infection | Care and treatment | Analysis | Interferon | Biological response modifiers | Hepatitis C virus | Health aspects | Therapy | Laboratories | Chronic infection | Critical care | Amino acids | Infections | Ribavirin | Clinical outcomes | Proteins | Genotype & phenotype | Hepatitis | Immunology | Hepatology | Post-translation | Pretreatment | Drug dosages | Genotypes | Statistical analysis | Liver diseases | Dendritic cells | Serum levels | Studies | Infectious diseases | CXCL10 protein | Biomarkers | Chemokines | Virus Replication/drug effects | Viral Load/drug effects | Dipeptidyl Peptidase 4/blood | Dipeptidyl Peptidase 4/genetics | Chemokine CXCL10/blood | Hepatitis C, Chronic/blood | Life Sciences | Hepatitis C, Chronic/drug therapy | Hepatitis C, Chronic/virology | Hepatitis C, Chronic/genetics | Chemokine CXCL10/genetics | Benzimidazoles/therapeutic use | Hepacivirus/physiology | Fluorenes/therapeutic use | Antiviral Agents/therapeutic use | Sofosbuvir/therapeutic use | Hepacivirus/drug effects | Ribavirin/therapeutic use
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2008, Volume 359, Issue 12, pp. 1238 - 1251
In this large clinical trial, aspirin plus extended-release dipyridamole was found to have an efficacy similar to that of clopidogrel in the prevention of... 
ACTIVE CONTROLLED-TRIALS | HIGH-RISK PATIENTS | TICLOPIDINE | TRANSIENT ISCHEMIC ATTACK | DOUBLE-BLIND | PREVENTION | RANDOMIZED CONTROLLED-TRIAL | ARTERIAL ORIGIN ESPRIT | CEREBRAL-ISCHEMIA | UMCG Approved | NON-INFERIORITY TRIALS | ISSUES | MEDICINE, GENERAL & INTERNAL | PLACEBO | DESIGN | WARFARIN | REGIMENS | Myocardial Infarction - epidemiology | Benzoates - therapeutic use | Ticlopidine - therapeutic use | Humans | Middle Aged | Male | Risk | Secondary Prevention | Aspirin - administration & dosage | Vascular Diseases - mortality | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Dipyridamole - adverse effects | Female | Stroke - epidemiology | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Dipyridamole - therapeutic use | Benzimidazoles - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Brain Ischemia - epidemiology | Stroke - prevention & control | Double-Blind Method | Kaplan-Meier Estimate | Proportional Hazards Models | Brain Ischemia - prevention & control | Factor Analysis, Statistical | Stroke - drug therapy | Ticlopidine - analogs & derivatives | Aged | Hemorrhage - chemically induced | Delayed-Action Preparations | Stroke (Disease) | Aspirin | Usage | Care and treatment | Dipyridamole | Clopidogrel | Health aspects | Stroke | Index Medicus | Abridged Index Medicus | Recurrence | Brain Ischemia | Benzimidazoles | Follow-Up Studies | Neurons and Cognition | Cognition | Hemorrhage | Drug Delivery Systems | Life Sciences | Angiotensin II Type 1 Receptor Blockers | Angiotensin-Converting Enzyme Inhibitors | Vascular Diseases | Mental Status Schedule | Retrospective Studies | Severity of Illness Index | Disability Evaluation | Benzoates | Drug Administration Schedule | International Cooperation | Ticlopidine | Myocardial Infarction | Platelet Aggregation Inhibitors | Santé publique et épidémiologie | Original | Dipyridamole/adverse effects/therapeutic use | Angiotensin-Converting Enzyme Inhibitors/therapeutic use | Recurrence/prevention & control | Benzoates/therapeutic use | Brain Ischemia/epidemiology/prevention & control | MEDICIN OCH HÄLSOVETENSKAP | Platelet Aggregation Inhibitors/administration & dosage/adverse | Combination | MEDICAL AND HEALTH SCIENCES | Aspirin/administration & dosage/adverse effects | Myocardial Infarction/epidemiology | Factor Analysis | Benzimidazoles/therapeutic use | Drug Therapy | Ticlopidine/adverse effects/analogs & derivatives/therapeutic use | effects/therapeutic use | Vascular Diseases/mortality | Hemorrhage/chemically induced | Stroke/drug therapy/epidemiology/prevention & control | Statistical | Kaplan-Meiers Estimate
Journal Article
Journal Article
Annals of internal medicine, ISSN 0003-4819, 2015, Volume 162, Issue 6, pp. 407 - 419
Journal Article
The American journal of medicine, ISSN 0002-9343, 2014, Volume 127, Issue 11, pp. 1075 - 1082.e1
Journal Article
BMC Gastroenterology, ISSN 1471-230X, 08/2015, Volume 15, Issue 1, p. 98
Background: The standard care of treatment of interferon plus ribavirin (plus protease inhibitor for genotype 1) are effective in 50 % to 70 % of patients with... 
Chronic hepatitis C | Olysio | Viekira Pak | Harvoni | Markov model | Cost-effectiveness | Sofosbuvir | DIAGNOSIS | INTERFERON-ALPHA-2B | VIRUS | MANAGEMENT | RIBAVIRIN | COMPENSATED CIRRHOSIS | HEPATOCELLULAR-CARCINOMA | THERAPY | DISEASE | INFECTION | GASTROENTEROLOGY & HEPATOLOGY | Interferons - economics | Markov Chains | Fluorenes - economics | Ribavirin - economics | Humans | Middle Aged | Simeprevir - economics | Fluorenes - therapeutic use | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Ritonavir - economics | Male | Interferons - therapeutic use | Uridine Monophosphate - economics | Benzimidazoles - economics | Polyethylene Glycols - therapeutic use | Simeprevir - therapeutic use | Sofosbuvir - economics | Ritonavir - therapeutic use | Female | Macrocyclic Compounds - economics | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Quality-Adjusted Life Years | Sofosbuvir - therapeutic use | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Genotype | Drug Therapy, Combination - economics | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Sulfonamides - therapeutic use | Cost-Benefit Analysis | Sulfonamides - economics | Uridine Monophosphate - analogs & derivatives | Uracil - economics | Antiviral Agents - economics | Drug Combinations | Uracil - analogs & derivatives | Economic aspects | Markov processes | Hepatitis C virus | Analysis
Journal Article
Liver international, ISSN 1478-3223, 2016, Volume 36, Issue S1, pp. 47 - 57
Journal Article
The American journal of cardiology, ISSN 0002-9149, 2012, Volume 110, Issue 3, pp. 453 - 460
Journal Article